FTO.nl maakt op haar websites gebruik van cookies. Een cookie is een klein bestandje dat met een pagina van een website wordt meegestuurd en door uw browser (tijdelijk) op de harde schrijf van uw computer of mobiele apparatuur wordt opgeslagen.
Novalla IS, Presloid JB, Travis Taylor R. RNA replication errors and the evolution of virus pathogenicity and virulence. Curr Opin Virol. 2014;9:143-7.
Duffy S. Why are RNA virus mutation rates so damn high? PLoS Biol. 2018;16(8):e3000003.
RIVM. Varianten van het coronavirus SARS-CoV-2. https://www.rivm.nl/coronavirus-covid-19/virus/varianten.
AlleCijfers.nl. Statistieken over het Coronavirus en COVID-19. https://allecijfers.nl/nieuws/statistieken-over-het-corona-virus-en-covid19/.
RIVM. Risicogroepen en COVID-19. https://www.rivm.nl/coronavirus-covid-19/risicogroepen.
El Bouazzaoui L, Bouma M, Cals J, et al. NHG-Standaard COVID-19. https://richtlijnen.nhg.org/standaarden/covid-19.
SWAB. Medicamenteuze behandeling voor patiënten met COVID-19 (infectie met SARS–CoV-2). https://swab.nl/nl/covid-19.
Kompaniyets L, Pennington AF, Goodman AB, et al. Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020-March 2021. Prev Chronic Dis. 2021;18:E66.
Eastman RT, Roth JS, Brimacombe KR, et al. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Cent Sci. 2020;6(5):672-683.
Gandhi RT. The Multidimensional Challenge of Treating Coronavirus Disease 2019 (COVID-19): Remdesivir Is a Foot in the Door. Clin Infect Dis. 2021;73(11):e4175-e4178.
Cooper CL, van Heeswijk RPG, Gallicano K, et al. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis. 2003;36(12):1585-92.
Owen DR, Allerton CMN, Anderson AS, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374(6575):1586-1593.
Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022; 386:1397-1408.
Persbericht Pfizer: Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results.
Hammond J. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Poster presented at: IDWeek 2022.
Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients. Clin Infect Dis. 2023;76(3):e342-e349.
Arbel R, Sagy YW, Hoshen M, et al. Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge. N Engl J Med. 2022;387(9):790-798.
Pfizer. Summary of Product Characteristics for PAXLOVI®, oktober 2023.
University of Liverpool. COVID-19 Drug Interaction. https://www.covid19-druginteractions.org/checker.
Global DDI Solutions. COVID-19 Drug-to-Drug Interactie Checker. https://www.covid19ddi.nl/.
FTO Onderwerpen
FTO
